rumbabor 250 mg / 100 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - atovaquonum,proguanili hydrochloridum - tabletti, kalvopäällysteinen - 250 mg / 100 mg - proguaniili, yhdistelmävalmisteet
rotop-nanohsa 0.5 mg valmisteyhdistelmä radioaktiivista lääkettä varten
rotop pharmaka gmbh - human albumin colloidal particles - valmisteyhdistelmä radioaktiivista lääkettä varten - 0.5 mg - teknetium(99mtc)nanokolloidi
epiduo 0,3 % / 2,5 % geeli
galderma nordic ab - benzoyl peroxide, adapalene - geeli - 0,3 % / 2,5 % - adapaleeni
levodonna 1.5 mg tabletti
sandoz a/s - levonorgestrel - tabletti - 1.5 mg - levonorgestreeli
efavirenz/emtricitabine/tenofovir disoproxil teva 600 mg / 200 mg / 245 mg tabletti, kalvopäällysteinen
teva b.v. - efavirenzum,tenofoviri disoproxili phosphas,emtricitabinum - tabletti, kalvopäällysteinen - 600 mg / 200 mg / 245 mg - emtrisitabiini, tenofoviiridisoproksiili ja efavirentsi
nicorette berrymint 1 mg/annos sumute suuonteloon, liuos
mcneil / jntl consumer health (finland) oy - nicotine - sumute suuonteloon, liuos - 1 mg/annos - nikotiini
verkazia
santen oy - siklosporiini - conjunctivitis; keratitis - silmätautien - vaikeiden vernal keratoconjunctivitis (vkc) lapset 4-vuotiaat ja nuorilla.
atovaquone/proguanil glenmark 250 mg / 100 mg tabletti, kalvopäällysteinen
glenmark arzneimittel gmbh - proguanili hydrochloridum,atovaquonum - tabletti, kalvopäällysteinen - 250 mg / 100 mg - proguaniili, yhdistelmävalmisteet
atovaquone glenmark 150 mg/ml oraalisuspensio
glenmark arzneimittel gmbh - atovaquone - oraalisuspensio - 150 mg/ml - atovakoni
circomax myco
zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiset suidaeille - siat (lihotus) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.